E-DRUG: The Guardian on access to cheaper AIDS drugs (cont)
-----------------------------------------------------------
In answer to one of Wilbert's last questions about why does the USA
government press other countries to remove those CL clauses when they are
explicitly permitted under Art 31 of TRIPS I believe the answer is that the
U.S has always considered the TRIPS agreement as the minimum level of
intellectual property that is acceptable. The U.S. has always reserved the
right to press countries to increase their patent protection through
bilateral negotiations. The pharmaceutical industry, as readers of E drug
know, is one of the major organizations pushing this aspect of U.S. trade
policy.
Joel Lexchin
Joel Lexchin MD
121 Walmer Rd.
Toronto, Ontario
CANADA M5R 2X8
Phone: (416)-964-7186
Fax: (416)-923-9515
e mail: joel.lexchin@utoronto.ca
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.